March 31st 2021, 12:30am
The agency granted approval to the revised label of Vyxeos to now include treatment for newly diagnosed therapy-related acute myeloid leukemia or disease with myelodysplasia-related changes in pediatric patients aged 1 and older.
February 11th 2021, 4:00pm
This week on the “CURE Talks Cancer” podcast, we spoke with Nicole Schulz, who was diagnosed with acute myeloid leukemia at the age of 14, about how her life changed as a result of her treatment and why she now lives life to the fullest.
February 2nd 2021, 10:00pm
Onureg, an oral form of the chemotherapy azacitidine, in older patients with acute myeloid leukemia who were in remission after chemotherapy contributed to longer survival outcomes, compared to placebo.
January 10th 2021, 3:00pm
The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.
December 31st 2020, 2:00pm
Here is a list of some recent trials that launched within the cancer space in December.
December 29th 2020, 2:00pm
Here are the top 10 FDA oncology drug approvals that you may have missed this year.
December 26th 2020, 3:00pm
A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.
December 24th 2020, 4:00pm
In this episode of the “CURE Talks Cancer” podcast, Dr. Dan Pollyea discusses the basics of AML, as well as treatment options currently available for patients.
December 18th 2020, 1:00am
Watch our Acute Myeloid Leukemia Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.
November 26th 2020, 2:00pm
Here is a list of some recent trials that launched within the cancer space in November.
How TikTok Helped One Survivor Discover Connection and Community
Certain Dietary Patterns May Be Associated with Lower Risk of Colorectal Cancer
Managing the Stress of Medical Leave and Insurance Forms
‘I’m Not Always Happy, But I’m Happy Right Now’ with Endometrial Cancer
